|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/27/21 Lazuriton Nano Biotechnology… Inc 10-Q 6/30/21 36:1.3M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 211K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 13K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 12K
12: R1 Cover HTML 62K
13: R2 Condensed Consolidated Balance Sheets HTML 57K
14: R3 Condensed Consolidated Balance Sheets HTML 21K
(Parentheticals)
15: R4 Condensed Consolidated Statements of Operations HTML 55K
(Unaudited)
16: R5 Condensed Consolidated Statements of Cash Flows HTML 43K
(Unaudited)
17: R6 Condensed Consolidated Statements of Changes in HTML 36K
Stockholders' Deficit (Unaudited)
18: R7 Nature of Operations and Summary of Accounting HTML 28K
Policies
19: R8 Accrued Expenses HTML 20K
20: R9 Due to Related Parties HTML 16K
21: R10 Income Taxes HTML 37K
22: R11 Subsequent Event HTML 15K
23: R12 Nature of Operations and Summary of Accounting HTML 50K
Policies (Policies)
24: R13 Accrued Expenses (Tables) HTML 19K
25: R14 Income Taxes (Tables) HTML 37K
26: R15 Nature of Operations and Summary of Accounting HTML 27K
Policies (Detail Narrative)
27: R16 Accrued Expenses (Details) HTML 21K
28: R17 Due to Related Parties (Detail Narrative) HTML 17K
29: R18 Income Taxes (Details) HTML 21K
30: R19 Income Taxes (Details 1) HTML 18K
31: R20 Income Taxes (Details 2) HTML 22K
32: R21 Income Taxes (Detail Narrative) HTML 21K
34: XML IDEA XML File -- Filing Summary XML 54K
11: XML XBRL Instance -- lznn_10q_htm XML 258K
33: EXCEL IDEA Workbook of Financial Reports XLSX 30K
8: EX-101.CAL XBRL Calculations -- lznn-20210630_cal XML 53K
10: EX-101.DEF XBRL Definitions -- lznn-20210630_def XML 53K
7: EX-101.LAB XBRL Labels -- lznn-20210630_lab XML 252K
9: EX-101.PRE XBRL Presentations -- lznn-20210630_pre XML 188K
6: EX-101.SCH XBRL Schema -- lznn-20210630 XSD 52K
35: JSON XBRL Instance as JSON Data -- MetaLinks 103± 140K
36: ZIP XBRL Zipped Folder -- 0001640334-21-002392-xbrl Zip 48K
EXHIBIT 31.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
I, Ching-Chia Chuang, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 of Lazuriton Nano Biotechnology (U.S.A.) Inc.; | |
|
|
| |
| 2 |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
|
|
|
|
| 3 | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
|
|
|
|
| 4 | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: | |
|
|
|
|
|
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
|
|
|
| 5 | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors: | |
|
|
| |
|
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
|
|
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: September 27, 2021 | By: | ||
|
| |||
|
| Principal Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/27/21 | 10-Q | ||
| For Period end: | 6/30/21 | |||
| List all Filings | ||||